Genmab to Acquire Dutch biotech for USD 8 Billion

The acquisition will allow for Copenhagen-based Genmab to add petosemtamab to its portfolio. This drug candidate has shown promising results in Phase II trials and is now being tested in Phase III as a treatment for head and neck cancer.

Petosemtamab has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA) — both as a monotherapy and in combination with pembrolizumab (Keytruda).